Regulators have moved quickly. After a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in June 2026, the European Commission approved pirtobrutinib in August 2026 for adults with CLL across all lines of therapy, and an equivalent decision from the US Food and Drug Administration is anticipated in the second half of 2026. An accompanying editorial by Davids argued that the two trials open the door for noncovalent BTK inhibition as initial therapy. On the surface, the case seems overwhelming: a drug that works at least as well as the incumbent, with dramatically better cardiovascular tolerability, seems destined to become the new default first choice.

But a correspondence published in Annals of Hematology by Boyi Chen and Shenxian Qian throws a careful, technically grounded brake on that enthusiasm. The authors highlight what they call a sequencing asymmetry, a structural imbalance in the evidence that neither of the new trials was designed to address. The order in which the two BTK inhibitor classes are given, they argue, matters enormously, and only one of the two possible orders is currently supported by randomized evidence. That order is the covalent-first sequence, and the argument for preserving it rests on the molecular biology of drug resistance as much as on clinical trial data.

The covalent BTK inhibitors, including ibrutinib, acalabrutinib and zanubrutinib, bind permanently to a cysteine residue at position 481 of the BTK kinase. Resistance to these drugs most often emerges through the C481S mutation, which replaces that cysteine with serine and blocks covalent attachment while leaving the binding pocket otherwise intact. Crucially, pirtobrutinib does not depend on covalent chemistry, so it retains activity against C481-mutant BTK. In the phase 1/2 BRUIN study, pirtobrutinib achieved a 73.3 percent response rate and a median progression-free survival of 19.6 months in patients whose disease had progressed on a covalent inhibitor, regardless of C481 status. In the phase III BRUIN CLL-321 trial, it outperformed idelalisib plus rituximab or bendamustine plus rituximab in this setting, with a hazard ratio of 0.54 and a median progression-free survival of 14.0 versus 8.7 months. A patient who begins treatment with a covalent inhibitor therefore keeps a rational, evidence-backed exit ramp if resistance develops.

The reverse sequence has no comparable data, and the resistance mechanisms give concrete reason for concern. Work by Wang and colleagues showed that acquired resistance to pirtobrutinib does not arise through C481 but through a distinct set of kinase-domain mutations: V416L, A428D, M437R, T474I and L528W. Of these, A428D and L528W conferred in vitro cross-resistance to ibrutinib and prevented multiple covalent BTK inhibitors from inhibiting the mutant enzyme. In other words, a patient who progresses on first-line pirtobrutinib may harbor leukemic clones that have compromised not just one drug but much of the covalent class, the very class that currently anchors relapse management. Notably, no patient in the Wang series acquired a new C481 mutation on pirtobrutinib, indicating that the two drug classes select largely distinct mutations, and that the mutations selected by the noncovalent agent can reduce sensitivity to covalent drugs. As Mato and colleagues observed in the original BRUIN publication, no information is currently available on the efficacy of covalent BTK inhibitors in patients who receive pirtobrutinib first and in whom resistance develops.

Davids offers a reasonable counterargument: many older patients with comorbidities may need only one or two lines of therapy over their remaining lifetime, making downstream resistance a less salient concern. For that subgroup, Chen and Qian concur that first-line pirtobrutinib is defensible, since a single effective line may be the realistic horizon. But CLL is not uniformly a disease of the very old. Younger patients, and those with unmutated IGHV genes or TP53 aberrations, can expect disease courses lasting ten to twenty years and multiple lines of treatment. Patients with del(17p) were even excluded from the CLL-313 trial. For these individuals, sequencing is not a footnote but the central strategic question, and spending the noncovalent agent first may forfeit options decades before they are needed.

Nor does toxicity, the argument that once favored abandoning covalent inhibitors altogether, justify skipping the class today. The cardiovascular case against ibrutinib has been substantially overtaken by the second-generation covalent agents. Zanubrutinib more than halved the rate of atrial fibrillation compared with ibrutinib in the ALPINE trial, 5.2 percent versus 13.3 percent, while improving progression-free survival, and acalabrutinib reduced atrial fibrillation in the ELEVATE-RR trial, 9.4 percent versus 16.0 percent, with non-inferior efficacy. The covalent-first strategy also preserves later options: beyond pirtobrutinib monotherapy after covalent inhibitor failure, the triplet of pirtobrutinib with venetoclax and rituximab has outperformed venetoclax plus rituximab in previously treated disease in BRUIN CLL-322, with a hazard ratio of 0.547. Frontline pirtobrutinib, by contrast, forgoes at present the only BTK-inhibitor class with phase III-validated salvage value.

The authors are careful to qualify their own argument. The cross-resistance evidence is preclinical, resting on in vitro potency and binding studies, and every patient in the Wang series who developed a non-C481 mutation had prior exposure to ibrutinib, so whether frontline pirtobrutinib selects the same mutational spectrum is unknown. Cross-resistance is also not strictly one-directional, since mutations such as L528W have been reported, less frequently, after covalent inhibitor therapy as well. These uncertainties, the authors stress, argue for caution and surveillance rather than regulatory delay. They also caution against treating BTK degraders, an emerging class of drugs that eliminate BTK rather than merely blocking it, as a ready safety net. Degraders such as NX-2127 can degrade kinase-impaired mutants including L528W, and early-phase studies of BGB-16673 and bexobrutideg report rapid, durable responses, but the evidence remains at the abstract level, pivotal trials are still accruing patients, and A428D can itself confer resistance to degrader therapy.

From this analysis flow four concrete recommendations. First, frontline trials of noncovalent BTK inhibitors should mandate BTK and PLCG2 mutation testing at progression, so the field learns which mutations first-line pirtobrutinib actually selects in previously untreated patients. Second, real-world registries should systematically track responses to covalent agents after pirtobrutinib failure, which the authors identify as the single most urgent evidence gap. Third, routine practice should incorporate BTK and PLCG2 testing whenever a patient progresses on any BTK inhibitor, since the mutational profile at relapse directly informs what can work next. Fourth, forthcoming guideline updates should explicitly address sequencing, and post-pirtobrutinib outcomes should be collected systematically while reverse-sequence data remain absent.

The BRUIN program has undeniably given CLL a highly effective drug, and its first-line efficacy is not in doubt. What remains unknown is what early use may cost at relapse. Until prospective sequencing data emerge, the authors conclude, the uncertainty argues for an individualized, sequencing-aware choice rather than a wholesale shift of the treatment default, particularly for the younger patients whose long disease courses give the order of therapy its greatest weight.

Subject of Research: Treatment sequencing and resistance mechanisms for first-line pirtobrutinib in chronic lymphocytic leukemia

Article Title: Sequencing asymmetry: the case for caution before first-line pirtobrutinib in chronic lymphocytic leukemia

Article References: Chen, B., & Qian, S. (2026). Sequencing asymmetry: the case for caution before first-line pirtobrutinib in chronic lymphocytic leukemia. Annals of Hematology, 105(9), Article 404. https://doi.org/10.1007/s00277-026-07264-x

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07264-x

Keywords: chronic lymphocytic leukemia, pirtobrutinib, BTK inhibitor, drug resistance, treatment sequencing, BTK C481S, kinase-domain mutations, BRUIN trials, cross-resistance, BTK degraders, hematology, clinical trials

The research, led by investigators including Huiquan Liu and Dong Qian, enrolled 1,242 patients with inoperable oesophageal squamous cell carcinoma from eight large hospitals across China between June 2018 and December 2023. More than half of all new cases of this disease occur in China, where the squamous subtype accounts for roughly 85 percent of oesophageal cancers, and a considerable share of patients are diagnosed with disease that cannot be surgically removed. Because no randomised controlled trial has ever directly compared the two sequencing strategies, the team turned to an increasingly influential methodology: target trial emulation, a framework that allows researchers to extract causal insights from observational data by designing the analysis as if it were a randomised trial.

The emulation was meticulous. Time zero was defined as the start of initial treatment, and patients were conceptually randomised into two groups: an upfront radiotherapy group, in which radiation began within a 42-day grace period, and a deferred radiotherapy group, in which radiation was delivered at any clinically appropriate later time. To eliminate the biases that plague retrospective studies, particularly immortal time bias and selection bias, the researchers used the clone-censor-weight technique. Every patient was duplicated into two identical copies, one assigned to each strategy. When a patient’s actual treatment trajectory departed from the assigned strategy, that copy was artificially censored, and inverse probability of censoring weighting corrected for the resulting informative dropout. The weighted clones formed a pseudo-population in which the two strategies could be compared as though patients had truly been randomised.

The cohort was split into 400 patients in the upfront radiotherapy group and 842 in the deferred group. Baseline characteristics were balanced using stabilised inverse probability of treatment weighting, with standardised mean differences below 0.1 for every covariate, including age, sex, body mass index, tumour location, and clinical stage. Notably, the deferred group actually carried a heavier tumour burden at baseline, with more advanced stage disease, thicker tumours, and lower haemoglobin levels, making the eventual survival advantage all the more remarkable. Most patients received platinum-based doublet chemotherapy alongside PD-1 or PD-L1 inhibitors, with median radiation doses of 60.0 Gy in the upfront group and 50.4 Gy in the deferred group.

The survival results were unambiguous. After a median follow-up of 34.8 months, 51.8 percent of patients in the upfront radiotherapy group had died, compared with 40.3 percent of those in the deferred group. Median overall survival reached 44.1 months with deferred radiotherapy versus 33.4 months with upfront radiotherapy, an adjusted hazard ratio of 0.699. Progression-free survival told the same story: 21.1 months versus 16.0 months, with an adjusted hazard ratio of 0.760. Under the clone-censor-weight analysis, the three-year overall survival rate was 57.5 percent with the deferred strategy against 41.9 percent with upfront radiation, an absolute difference of 15.6 percentage points. Three-year progression-free survival was 33.8 percent versus 22.4 percent.

The robustness of these findings was tested through nine separate sensitivity analyses, and the conclusion held every time. The grace period was varied to 21 and 63 days; overlap weighting was applied to focus on clinically comparable patients; hospital-level variability was modelled with mixed effects; missing data were multiply imputed; and analyses were restricted to the 1,225 patients who received PD-1 inhibitors. Landmark analyses restricted to patients alive and progression-free at day 42, and a reclassification comparing patients who started with radiation against those who started with immunotherapy, all favoured the deferred approach. E-values of 2.460 for overall survival indicated that only very strong unmeasured confounding could plausibly explain away the association. Subgroup analyses across sex, age, residence, performance status, and tumour characteristics showed a consistent direction of benefit.

Safety data added a further dimension to the debate. Severe oesophageal fistula, a feared complication in which a hole forms in the irradiated oesophageal wall, occurred in 9.0 percent of the upfront radiotherapy group compared with 4.8 percent of the deferred group, and fatal fistulas claimed eight patients in the upfront arm versus seven in the deferred arm despite its smaller size. This pattern echoes prospective data: in the EC-CRT-001 trial, which combined chemoradiotherapy with concurrent immunotherapy, the fistula rate was 14.3 percent, whereas in EC-CRT-002, which used induction chemoimmunotherapy before deferred radiation, it was just 3.5 percent. The most likely explanation is that induction systemic therapy shrinks the tumour before radiation begins, reducing local invasion and making irradiation safer. Conversely, grade 4 leukopenia and neutropenia were somewhat more frequent in the deferred group, possibly reflecting depleted bone marrow reserve after prolonged systemic therapy.

The biological rationale for these findings is as intriguing as the statistics. Radiation is widely recognised to remodel anti-tumour immunity, and hypofractionated regimens can synergise with immunotherapy by releasing tumour antigens and activating immune cells. But definitive oesophageal chemoradiotherapy cannot routinely use hypofractionation because of fistula risk, so patients endure weeks of conventional fractionation. Experimental work has shown that X-ray irradiation dilates lymphatic vessels, stagnates lymph flow, and damages high endothelial venules, the specialised structures that allow immune cells to enter lymph nodes. A secondary analysis of pooled randomised trial data found that higher radiation dose-volume parameters in lymphatic drainage regions were associated with impaired T-cell activation and worse prognosis. In other words, early radiation may inadvertently sabotage the very lymph node machinery that checkpoint inhibitors rely upon to prime anti-tumour T cells.

The authors are careful about what their study can and cannot prove. Because radiation dose, chemotherapy cycles, and immunotherapy cycles are consequences of the assigned strategy rather than baseline characteristics, they were not adjusted for as confounders. Patients in the upfront group received a higher median radiation dose, while those in the deferred group completed more cycles of chemoimmunotherapy, so the observed survival gap may reflect differences in overall treatment intensity rather than sequence alone. The findings therefore represent the marginal total effect of two real-world strategies, not definitive evidence that radiation timing independently drives survival. Other limitations include the retrospective design, the absence of time-varying covariates, non-protocolised tumour assessments, and incomplete records of radiation target volumes and chemotherapy regimens.

Even with those caveats, the implications for clinical practice are immediate and potentially practice-changing. For the many patients with inoperable oesophageal squamous cell carcinoma who face this decision each year, the evidence now suggests that starting with chemoimmunotherapy and deferring radiation may extend both life and time without progression, while reducing the risk of a devastating oesophageal fistula. The survival rates observed in this retrospective cohort align closely with those reported in prospective phase II trials, lending credibility to the results. Ongoing randomised trials will ultimately determine whether sequence, intensity, or their interaction explains the difference, but for now, this study of more than 1,200 patients provides the strongest real-world signal yet that in the immunotherapy era, patience with radiation may be a virtue worth cultivating.

Subject of Research: Sequencing of radiotherapy with first-line chemoimmunotherapy in inoperable oesophageal squamous cell carcinoma

Article Title: Upfront or deferred radiotherapy combined with chemoimmunotherapy for inoperable oesophageal squamous cell carcinoma: a target trial emulation in China

Article References: Liu, H., Guan, J., Zhang, W., Li, D., Fu, X., Li, L., Zang, C., He, Y., Tian, J., Tong, Z., Huang, W., & Qian, D. (2026). Upfront or deferred radiotherapy combined with chemoimmunotherapy for inoperable oesophageal squamous cell carcinoma: a target trial emulation in China. eClinicalMedicine, 100, Article 104236. https://doi.org/10.1016/j.eclinm.2026.104236

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104236

Keywords: oesophageal cancer, squamous cell carcinoma, radiotherapy, chemoimmunotherapy, immune checkpoint inhibitors, target trial emulation, clone-censor-weight, overall survival, oesophageal fistula, China, eClinicalMedicine, treatment sequencing

Metastatic colorectal cancer remains one of the most common causes of cancer death worldwide. According to estimates cited by the study’s authors from the International Agency for Research on Cancer, colorectal cancer accounts for a substantial share of new cancer diagnoses globally, and Japan, where the study was conducted, maintains detailed national cancer statistics reflecting the disease’s heavy burden. Once patients progress through initial chemotherapy regimens and targeted combinations, they enter a refractory stage where only a handful of options remain. Regorafenib, an oral multikinase inhibitor that blocks tumor angiogenesis and oncogenic signaling pathways, and trifluridine/tipiracil, an oral nucleoside antimetabolite combination that thwarts tumor DNA repair, are the two pillars of this late-line setting. Both extend survival compared with placebo in randomized trials, but no definitive evidence had established which sequence delivers better outcomes when both drugs are ultimately available to a patient.

The OSERO study, led by Takeshi Kawakami of the Shizuoka Cancer Center with Eiji Oki of Kyushu University serving as principal investigator, was designed to close that evidence gap prospectively rather than retrospectively. Sponsored by the Kyushu Study group of Clinical Cancer and funded by Bayer Yakuhin, the study enrolled patients across 42 Japanese institutions who were scheduled to begin later-line treatment with regorafenib or trifluridine/tipiracil, with or without bevacizumab. Patients were assigned to three cohorts: cohort A received regorafenib monotherapy, cohort B received trifluridine/tipiracil alone, and cohort C received trifluridine/tipiracil plus bevacizumab, an anti-VEGF antibody that starves tumors of their blood supply. The primary endpoint was overall survival, the most clinically meaningful measure of whether a treatment sequence prolongs life.

In total, 468 patients were analyzed, with 154 in the regorafenib cohort, 82 in the trifluridine/tipiracil cohort, and 232 in the trifluridine/tipiracil plus bevacizumab cohort. The raw numbers told an initially striking story. Patients starting with regorafenib had a median overall survival of 12.2 months, compared with 7.5 months for those starting with trifluridine/tipiracil alone and 10.6 months for those receiving the combination with bevacizumab. Rates of proceeding to a scheduled second-line treatment also differed markedly: 65.6 percent of regorafenib starters went on to further therapy, compared with 37.8 percent of the trifluridine/tipiracil-alone group and 62.9 percent of the bevacizumab combination group.

But raw comparisons in observational research are notoriously misleading. Clinicians do not assign these drugs at random; they weigh each patient’s performance status, prior treatment history, organ function, and the aggressiveness of the disease. Patients selected for one drug may be systematically healthier or sicker than those selected for another, a phenomenon known as confounding by indication. To address this, the investigators applied stabilized inverse probability of treatment weighting, a statistical technique derived from propensity score modeling. Each patient was assigned a weight reflecting the probability of receiving the treatment they actually received given their baseline characteristics, effectively creating a pseudo-population in which treatment assignment was independent of measured confounders. This method, widely used in pharmacoepidemiology, cannot eliminate bias from unmeasured variables, but it represents the strongest adjustment feasible outside a randomized trial.

After this adjustment, the survival difference between the two principal strategies evaporated. Median overall survival was 12.2 months for the regorafenib-first sequence and 10.6 months for the trifluridine/tipiracil-plus-bevacizumab sequence, with a hazard ratio of 1.03 and a 95 percent confidence interval of 0.81 to 1.30, and a P value of 0.837. A hazard ratio so close to 1.0, with a confidence interval comfortably spanning unity, indicates essentially no detectable survival advantage for either sequence. In practical terms, the total length of survival a patient could expect from the two-drug sequence appeared similar regardless of which agent was deployed first.

The safety data, however, revealed a sharp and clinically consequential divide. Grade 3 or higher adverse events occurring in more than 10 percent of patients differed by cohort. In the regorafenib group, the dominant toxicities were hand-foot syndrome, proteinuria, and hypertension, classic signatures of the drug’s anti-angiogenic and multikinase activity. Hand-foot syndrome, a painful inflammation of the palms and soles, can severely limit daily function and often forces dose reductions. In the trifluridine/tipiracil groups, both with and without bevacizumab, the principal toxicities were hematologic: neutropenia, a depletion of infection-fighting white blood cells, and anemia. These contrasting profiles mean that the two strategies impose different burdens on different patients, and the authors concluded that treatment selection may reasonably depend on the safety profile of each drug in the context of individual patient characteristics.

The findings arrive at a moment when the late-line colorectal cancer landscape is shifting. The addition of bevacizumab to trifluridine/tipiracil gained momentum after a series of Japanese investigator-initiated studies, including the C-TASK FORCE, TAS-CC3, TAS-CC4, and BiTS trials, demonstrated the feasibility and activity of the combination. That momentum culminated in the international phase 3 SUNLIGHT trial published in the New England Journal of Medicine in 2023, which showed that trifluridine/tipiracil plus bevacizumab improved survival over trifluridine/tipiracil alone in refractory disease, cementing the combination in international guidelines from the National Comprehensive Cancer Network and the European Society for Medical Oncology. Meanwhile, the FRESCO-2 trial introduced fruquintinib, another oral angiogenesis inhibitor, as a further option, and earlier work such as the Japanese REGOTAS propensity score analysis had attempted retrospective comparisons of regorafenib and trifluridine/tipiracil. Prior work by several of the same OSERO investigators had also suggested that survival benefits accumulate with the number of active drugs a patient receives, underscoring why sequencing questions matter so much.

What distinguishes OSERO is its prospective design. Most evidence comparing these agents has come from retrospective chart reviews or registry analyses, which are vulnerable to selection bias and incomplete data. By registering patients before treatment began, at the moment the clinician committed to a strategy, the investigators captured the true decision point of interest. The study was conducted in accordance with the Declaration of Helsinki, approved by the Kyushu University institutional review board, and all participants provided written informed consent. The breadth of participation, spanning 42 institutions from Shizuoka to Hokkaido to Kyushu, lends the results a real-world texture that single-center trials often lack, reflecting the heterogeneous patient populations and clinical judgments that define everyday oncology practice.

For clinicians, the message is one of flexibility rather than a new mandate. Because the two sequences yielded comparable adjusted survival, oncologists can tailor the choice to the patient in front of them: a patient with poorly controlled hypertension or painful hand-foot syndrome risk factors might be steered toward trifluridine/tipiracil with bevacizumab, while one with marginal bone marrow reserve might better tolerate regorafenib. For patients, the study offers reassurance that neither choice forecloses a meaningful survival opportunity, since both drugs can typically be delivered in sequence. The authors caution that, as an observational study, OSERO cannot rule out residual confounding, and randomized confirmation remains the gold standard. Yet with a randomized head-to-head sequencing trial unlikely to be mounted, this prospectively collected, statistically adjusted evidence from nearly 500 patients stands as the clearest guidance available, and it suggests that in the final chapters of metastatic colorectal cancer treatment, the order of the last two drugs matters far less than ensuring patients can safely receive both.

Subject of Research: Treatment sequencing of regorafenib and trifluridine/tipiracil in later-line metastatic colorectal cancer

Article Title: A prospective observational study of treatment sequencing with regorafenib and FTD/TPI in metastatic colorectal cancer: The OSERO study

Article References: A prospective observational study of treatment sequencing with regorafenib and FTD/TPI in metastatic colorectal cancer: The OSERO study. (n.d.). https://doi.org/10.1038/s41416-026-03620-w

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03620-w

Keywords: metastatic colorectal cancer, regorafenib, trifluridine/tipiracil, bevacizumab, treatment sequencing, overall survival, observational study, propensity score, inverse probability weighting, chemotherapy, drug safety, clinical oncology

The study, conducted by researchers at Pfizer Japan, IQVIA Solutions Japan, and Pfizer Inc., built a hybrid model combining a decision tree for the initial induction phase with a Markov framework for maintenance and all subsequent lines of therapy. Patients who failed their first advanced therapy were assumed to switch to an alternative agent, then to a basket of remaining drugs, and eventually to best supportive care if they continued to lose response. The simulated population mirrored Japanese trial participants newly starting advanced therapy, with a mean age of 42.4 years and a mean body weight of 59.7 kilograms. Efficacy and safety inputs came from a Bayesian network meta-analysis covering ten advanced therapies, supplemented with Japan-specific costs drawn from a nationwide claims database and adjusted to 2025 price levels.

The economics were evaluated from the perspective of the Japanese payer, with both costs and quality-adjusted life years discounted at an annual rate of 2.0 percent, in line with national health technology assessment guidelines. The willingness-to-pay threshold was set at JPY 7,500,000 per QALY, roughly USD 49,547, the benchmark used in Japan’s system for designated intractable diseases, a category to which ulcerative colitis belongs. Only serious infections were modelled as adverse events, a choice consistent with previous economic evaluations in this therapeutic area, because they drive the greatest costs and quality-of-life impairment while safety profiles across the drug classes remain broadly similar.

The central result was striking in its clarity. Among all 79 sequences evaluated, starting with etrasimod and following with upadacitinib produced the greatest lifetime health benefit, a total of 17.801 quality-adjusted life years. Four strategies anchored the efficiency frontier, the curve tracing the most efficient options at each cost level: infliximab followed by ustekinumab, infliximab followed by etrasimod, infliximab followed by upadacitinib, and etrasimod followed by upadacitinib. Each successive step along the frontier bought more health at an incremental cost-effectiveness ratio comfortably below the Japanese threshold, culminating in etrasimod followed by upadacitinib at JPY 6,684,442 per QALY, which remained cost-effective and delivered the most value overall.

The mechanistic logic behind the winning sequence is instructive. The network meta-analysis showed that upadacitinib, an oral JAK inhibitor, achieved the highest remission and response rates among patients who had already been exposed to advanced therapy, making it a particularly powerful second-line option. Etrasimod, which traps lymphocytes in lymph nodes by modulating the S1P receptor on their surface and thereby blunts intestinal inflammation while preserving systemic immune surveillance, showed favorable efficacy and safety across multiple endpoints in treatment-naïve patients. Pairing the two oral agents in that order therefore maximized cumulative quality-adjusted survival, and etrasimod outperformed ozanimod, its identically priced oral counterpart, on maintenance response, remission, and serious infection rates in the comparative evidence underpinning the model.

Sensitivity analyses revealed where the conclusion could shift. When infliximab and adalimumab biosimilars were introduced into the model, the picture changed materially. Because biosimilar infliximab costs JPY 13,860 per 100-milligram vial compared with JPY 35,981 for the originator, a first-line biosimilar infliximab sequence followed by upadacitinib became the most cost-effective strategy, pushing the etrasimod-upadacitinib combination above the threshold. Yet the authors caution that real-world biosimilar uptake in Japanese ulcerative colitis remains around 20 percent, and a survey found that 85 percent of Japanese inflammatory bowel disease patients were unaware biosimilars even existed. Under Japan’s high-cost medical expense benefit program, out-of-pocket costs are so constrained that patients have little financial incentive to switch.

Other scenario analyses tested alternative assumptions about disease progression and treatment intensity. Allowing dose escalation of tofacitinib, upadacitinib, and ustekinumab during maintenance left etrasimod followed by upadacitinib as the most cost-effective sequence, though with a narrower margin. Assuming patients never transitioned from later-line therapy to best supportive care shifted the optimal sequence to etrasimod followed by ustekinumab. Applying higher colectomy rates, informed by Japanese national database studies, moved infliximab followed by upadacitinib to the top. The fragility of the base-case result was further underlined by the one-way sensitivity analysis, in which placebo-arm maintenance parameters and infliximab’s relative efficacy had the largest influence on the incremental net monetary benefit.

The study carries important caveats that temper any temptation to treat its ranking as clinical gospel. Efficacy estimates derive from a network meta-analysis of trials published through November 2022, and such analyses for ulcerative colitis are known to suffer from heterogeneity in prior biologic exposure, baseline disease activity, and outcome definitions. Real-world evidence, which now exists for several of the agents, was excluded because of incomparability across studies. Serious infections were the only adverse event modelled, leaving unquantified risks such as major cardiovascular events, venous thromboembolism, herpes zoster, and malignancy, factors that matter greatly in real treatment choices. Utility values came largely from non-Japanese populations, and the transition rate from late-line therapy to best supportive care was borrowed from a United States claims database.

There is also the question of who conducted the analysis. All clinical authors are Pfizer employees or contractors funded by Pfizer Japan, and the company financed the research and publication. The acknowledged conflicts do not invalidate the mathematics, but they do mean the framing of etrasimod, a Pfizer drug, as the preferred starting point deserves independent scrutiny, particularly given how sensitive the results were to pricing assumptions around cheaper biosimilars.

For clinicians and policymakers, the study’s value lies less in crowning a single winner than in demonstrating that sequencing choices carry quantifiable economic and health consequences over a lifetime of disease. The authors themselves stress that the findings should complement, not dictate, clinical judgement, alongside patient age, comorbidities, pregnancy plans, and personal preference. As Japan’s ulcerative colitis population grows, having expanded roughly 1.4-fold over eight years, and as real-world data accumulate on the newer oral agents, future updates of this model will be needed to confirm whether the etrasimod-then-upadacitinib pathway truly delivers the best value in everyday practice rather than in simulation.

Subject of Research: Cost-effectiveness modeling of advanced therapy sequences for moderately to severely active ulcerative colitis in Japan

Article Title: Comparative Cost-Effectiveness of Advanced Treatment Sequences for Moderately to Severely Active Ulcerative Colitis in Japan

Article References: Kamei, K., Enami, M., Matsuda, H., Yamagami, K., Dai, Y., Hoshi, M., Law, E. H., & Yuasa, A. (2026). Comparative Cost-Effectiveness of Advanced Treatment Sequences for Moderately to Severely Active Ulcerative Colitis in Japan. Advances in Therapy. https://doi.org/10.1007/s12325-026-03757-3

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03757-3

Keywords: ulcerative colitis, cost-effectiveness, etrasimod, upadacitinib, infliximab, S1P receptor modulators, JAK inhibitors, network meta-analysis, QALY, Japan, biosimilars, treatment sequencing